Compare F5 Inc (FFIV) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
F5 Inc vs State Street SPDR S&P Biotech ETF — how do they compare? F5 Inc trades at $478.52 (market cap $26.14B), while State Street SPDR S&P Biotech ETF trades at $154.31 (market cap $10.11B). The key difference: F5 Inc is far larger — about 2.6× State Street SPDR S&P Biotech ETF's market cap, and F5 Inc is trading nearer its 52-week high, State Street SPDR S&P Biotech ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold F5 Inc for 38 Days and State Street SPDR S&P Biotech ETF for 37 Days on average.
| FFIV | XBI | |
|---|---|---|
Market Cap | $26.14B | $10.11B |
Volume | 503,146 | 12,903,266 |
Sector | Technology | Broad Market / Factor |
52-Week High | $469.79 | $169.55 |
52-Week Low | $223.99 | $104.99 |
Typical Hold Time | 38 Days | 37 Days |
Enterprise Value | $24.78B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FFIV trades at $467.57, up 0.2% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $4.73 beating expectations of $4.00. Revenue grew to $3.09B in 2025, and net income margin improved to 21.95%. Recent news highlights F5's leadership in WAAP platforms and AI security partnerships, reinforcing its market position.
The outlook remains positive given earnings momentum and strategic initiatives in AI security, though valuation multiples like P/E of 36.78 suggest premium pricing. Risks include competitive pressures and execution challenges in integrating new technologies. Analyst consensus is mixed with a $416.60 price target below current levels, indicating caution despite growth prospects.
XBI trades at $153.34, up 2.07% today, but faces bearish technical signals with 17 sell indicators versus 4 buys. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from recent M&A activity and positive clinical trial catalysts. Current price sits near resistance at $154, with support at $147.
Biotech sector optimism is growing with cancer vaccine breakthroughs and improved capital access, though XBI's 0.35% expense ratio is higher than broader healthcare ETFs. Key risks include sector volatility and regulatory uncertainty, while analyst consensus remains neutral with 100% hold rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About F5 Inc
F5 is a market leader in the application delivery controller market. The company sells products for networking traffic, security, and policy management. Its products ensure applications are safely routed in efficient manners within on-premises data centers and across cloud environments. More than half of its revenue is based on providing services, and its three customer verticals are enterprises, service providers, and government entities. The Seattle-based firm was incorporated in 1996 and generates sales globally.
Read more on FFIV →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
